12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Delamanid: Extension study data

Data from 421 MDR-TB patients in the open-label Study 242-10-116 extension of the double-blind, international Phase IIb 242-07-204 trial showed that 75% of patients who received delamanid for >=6 months were classified as having "favorable outcomes" vs. 55% of patients who received delamanid for <=2 months (p<0.001). All patients received a standard background regimen for multidrug-resistant TB as recommended by the World Health Organization. Researchers classified...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >